
Afzanna 20mg Tablet
Salt Composition: Afatinib
Expiry Date: 01/2028
Inclusive of all taxes
28 tablets in Bottle
About The Product
Lung Cancer, monotherapy
Description
Afzanna 20mg tablet is a targeted anti-cancer medication which is highly recommended to lung cancer patients by healthcare professional. The medicine works by blocking epidermal growth factor receptor (EGFR) which is involved in the growth and multiplication of cancer cells in the body, thereby helping to slow or stop tumor progression.
Medication contains Afatinib as its active ingredient which is present in its salt composition which helps to slow down the process of formation of cancer cells in the body. Strict medical guidelines must be followed during the treatment to ensure safety and effectiveness of the treatment.
Indication
Non small cell lung cancer
Common side effects
- Afzanna 20mg tablet cause side effects in some patients and these can vary from mild to moderate depending on individual response and overall health outcomes.
- Discuss with doctor if the symptoms persist: ● Loss of appetite ● Abdominal pain ● Interstitial lung disease (ILD) ● Severe diarrhea or dehydration ● Liver problems ● Diarrhea ● Mouth sores ● Acne or skin rash ● Dry skin or itching ● Eye irritation or dryness ● Respiratory infections
Dosage and duration
- Afzanna 20mg tablet is a prescription based medication, doctors suggest consuming the medicine on an empty stomach at the same time everyday with a whole glass of water.
- Never skip or double the dose, if you miss a dose take the next one at the schedule time unless your advises otherwise.
- Taking it in the wrong way may cause serious side effects and lead to complications.
Mechanism of the action
Lung cancer is caused by epidermal growth factor receptor (EGFR) which is a primary cause of cancer cell growth and multiplication of cancer cells in the body. Afzanna tablet work by binding and inhibiting the enzyme EGFR, thereby helping to stop the growth and multiplication of cancer cells.
Doctors prescribed this medication to patients whose cancer cell is driven by EGFR mutation, based on their medical condition and treatment plan.
Safety advice
FAQs
Afzanna 20mg tablet treats non small cell lung cancer (NSCLC) by blocking the growth of abnormal protein causing cancer cell in the body.
Reference
• Wecker, H., & Waller, C. F.
(2018). Afatinib.
Small Molecules in Oncology, 199-215. • Dungo, R. T., & Keating, G.
M. (2013).
Afatinib: first global approval. Drugs, 73(13), 1503-1515. • Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P.
(2017). Clinical pharmacokinetics and pharmacodynamics of afatinib.
Clinical pharmacokinetics, 56(3), 235-250. • Nelson, V., Ziehr, J., Agulnik, M., & Johnson, M. (2013).
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and therapy, 135-143. • Keating, G.
M. (2014).
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs, 74(2), 207-221.
Medical Disclaimer
Accurate, reviewed information to support informed healthcare decisions
Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.
The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.
This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.
Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.
